Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome.
The outcome and cause of death of each lung disease directly associated with rheumatoid arthritis (RA-LD) have been poorly investigated. A retrospective study was conducted of 144 patients with RA-LD, in whom the median follow-up period after the initial visit for a respiratory examination was 4.5 yrs. A total of 57 patients were identified with usual interstitial pneumonia (UIP), 31 with bronchiectasis, 16 with nonspecific interstitial pneumonia (NSIP), 11 with bronchiolitis, five with organising pneumonia (OP), five with diffuse alveolar damage (DAD) and 19 with combined disease. The 5-yr survival rates were 36.6% in the UIP group, 87.1% in the bronchiectasis group, 93.8% in the NSIP group, 88.9% in the bronchiolitis group, 60.0% in the OP group and 20.0% in the DAD group. Survival of patients with DAD was worse than that of patients with UIP. Overall, survival of patients with UIP was worse than that of patients with bronchiectasis, NSIP or bronchiolitis. Of the 144 patients, 71 (49.3%) died, of whom 58 (81.7%) died due to respiratory lesions. Of patients with RA-LD, patients with DAD experienced the highest mortality, and the survival of patients with UIP was worse than that of patients with NSIP.
Tsuchiya
Y
Y
Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, 1696 Itai, Kumagaya, Saitama 360-0105, Japan. caeser-salad.2corn-soups@nifty.com
Takayanagi
N
N
Sugiura
H
H
Miyahara
Y
Y
Tokunaga
D
D
Kawabata
Y
Y
Sugita
Y
Y
D000368:Aged; D001172:Arthritis, Rheumatoid / Q000401:mortality*; D001987:Bronchiectasis / Q000401:mortality; D001988:Bronchiolitis / Q000401:mortality; D015897:Comorbidity; D005260:Female; D006801:Humans; D054988:Idiopathic Interstitial Pneumonias / Q000401:mortality; D054990:Idiopathic Pulmonary Fibrosis / Q000401:mortality; D008171:Lung Diseases / Q000401:mortality*; D008297:Male; D012189:Retrospective Studies; D012907:Smoking / Q000453:epidemiology; D015996:Survival Rate; D016896:Treatment Outcome